Company Profile

Angstrom Pharmaceuticals Inc
Profile last edited on: 3/11/19      CAGE: 5HYZ2      UEI:

Business Identifier: Cell migration, invasion, angiogenesis and neovascularization
Year Founded
1996
First Award
1999
Latest Award
2001
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

990 Highland Drive Suite 314
Solana Beach, CA 92075
   (858) 314-2356
   info@angstrominc.com
   www.angstrominc.com
Location: Single
Congr. District: 49
County: San Diego

Public Profile

Angstrom Pharmaceuticals Inc is a pharmaceutical firm focused to discovery of drugs that block the docking of an extracellular regulatory protein (ligand) to its receptor found on the outside of a cell - when this event is responsible for initiating a disease state. This is a new class of proprietary drugs that treat diseases involving cell migration, invasion, and metastasis. Ångstrom’s lead product, Å6 peptide, is a First-in-Class “Oncoparalytic”, stopping tumors from metastasizing by paralyzing cancer cells.Angstrom is developing new compounds for the treatment of diseases that are mediated through cell migration, invasion, angiogenesis and neovascularization. This includes cancer and wet age-related macular degener

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2001 2 NIH $510,156
Project Title: Peptide Anatgonists Of Urokinase Plasminogen Activator
1999 1 NIH $100,017
Project Title: Anti-Angiogenic Peptides Derived From Human Kininogen

Key People / Management

  Malcolm Finlayson -- President and Ceo

  Terence R Jones -- Founder CTO

  Andrew P Mazar

Company News

There are no news available.